Skip to main content
Top
Published in: BMC Nephrology 1/2015

Open Access 01-12-2015 | Case report

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib

Authors: Arun Rajasekaran, Thuy-Trang Ngo, Maen Abdelrahim, William Glass, Amber Podoll, Srdan Verstovsek, Ala Abudayyeh

Published in: BMC Nephrology | Issue 1/2015

Login to get access

Abstract

Background

Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasm (MPN) characterized by the predominant proliferation of megakaryocytes and granulocytes in the bone marrow, leading to the deposition of fibrous tissue, and by a propensity toward extramedullary hematopoiesis. Renal involvement in PMF is rare, but kidney tissue samples from these patients reveal MPN-related glomerulopathy, a recently discovered condition, in the late stages of the disease.

Case presentation

We present the first case described in the medical literature of a patient with early renal glomerular involvement in PMF/MPN. A 60-year-old man with stage 4 chronic kidney disease and a recent diagnosis of PMF (within 4 weeks of presentation at our renal division) presented with generalized body swelling, acute kidney injury, and massive nephrotic-range proteinuria. Kidney biopsy was performed to determine the etiology of the patient’s renal dysfunction and revealed early renal glomerular involvement that was histologically characteristic of MPN-related glomerulopathy. Early diagnosis and prompt medical management returned the patient’s kidney functionality to the levels seen on initial presentation at our hospital.

Conclusion

Large studies with long follow-up durations are necessary to identify and categorize the risk factors for the development of MPN-related glomerulopathy, to standardize therapeutic regimens, and to determine whether aggressive management of the myelofibrosis slows the progression of kidney disease.
Literature
1.
2.
go back to reference Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14–22.CrossRefPubMed Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14–22.CrossRefPubMed
3.
go back to reference Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275–90.CrossRefPubMed Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275–90.CrossRefPubMed
4.
go back to reference Bello Nicolau I, Conde Zurita JM, Barrientos Guzman A, Gutierrez Millet V, Ruilope Urioste LM, Prieto Carles C, et al. Essential thrombocytosis with acute renal failure due to bilateral thrombosis of the renal arteries and veins. Nephron. 1982;32(1):73–4.CrossRefPubMed Bello Nicolau I, Conde Zurita JM, Barrientos Guzman A, Gutierrez Millet V, Ruilope Urioste LM, Prieto Carles C, et al. Essential thrombocytosis with acute renal failure due to bilateral thrombosis of the renal arteries and veins. Nephron. 1982;32(1):73–4.CrossRefPubMed
5.
go back to reference Yuzawa Y, Sato W, Masuda T, Hamada Y, Tatematsu M, Yasuda Y, et al. Acute kidney injury presenting a feature of leukemic infiltration during therapy for chronic myelogenous leukemia. Intern Med. 2010;49(12):1139–42.CrossRefPubMed Yuzawa Y, Sato W, Masuda T, Hamada Y, Tatematsu M, Yasuda Y, et al. Acute kidney injury presenting a feature of leukemic infiltration during therapy for chronic myelogenous leukemia. Intern Med. 2010;49(12):1139–42.CrossRefPubMed
6.
go back to reference Bardy A, Tiple A, Rabant M, Kemeny JL, El Karoui K, Hermet M, et al. The myeloproliferative neoplasms-related glomerulopathy. Rev Med Interne. 2014;35(4):222–30.CrossRefPubMed Bardy A, Tiple A, Rabant M, Kemeny JL, El Karoui K, Hermet M, et al. The myeloproliferative neoplasms-related glomerulopathy. Rev Med Interne. 2014;35(4):222–30.CrossRefPubMed
7.
go back to reference Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, et al. Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011;80(7):753–9.CrossRefPubMed Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, et al. Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011;80(7):753–9.CrossRefPubMed
8.
go back to reference Martyre MC. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma. 1995;20(1–2):39–44.CrossRefPubMed Martyre MC. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma. 1995;20(1–2):39–44.CrossRefPubMed
9.
go back to reference Martyre MC, Magdelenat H, Bryckaert MC, Laine-Bidron C, Calvo F. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1991;77(1):80–6.CrossRefPubMed Martyre MC, Magdelenat H, Bryckaert MC, Laine-Bidron C, Calvo F. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1991;77(1):80–6.CrossRefPubMed
10.
go back to reference Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol. 2008;19(1):12–23.CrossRefPubMed Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol. 2008;19(1):12–23.CrossRefPubMed
11.
go back to reference Jiang T, Che Q, Lin Y, Li H, Zhang N. Aldose reductase regulates TGF-beta1-induced production of fibronectin and type IV collagen in cultured rat mesangial cells. Nephrology (Carlton). 2006;11(2):105–12.CrossRef Jiang T, Che Q, Lin Y, Li H, Zhang N. Aldose reductase regulates TGF-beta1-induced production of fibronectin and type IV collagen in cultured rat mesangial cells. Nephrology (Carlton). 2006;11(2):105–12.CrossRef
12.
go back to reference Christensen AS, Moller JB, Hasselbalch HC. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2014;38(4):490–5.CrossRefPubMed Christensen AS, Moller JB, Hasselbalch HC. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2014;38(4):490–5.CrossRefPubMed
13.
go back to reference Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119(14):3219–25.CrossRefPubMed Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119(14):3219–25.CrossRefPubMed
Metadata
Title
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Authors
Arun Rajasekaran
Thuy-Trang Ngo
Maen Abdelrahim
William Glass
Amber Podoll
Srdan Verstovsek
Ala Abudayyeh
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2015
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-015-0121-6

Other articles of this Issue 1/2015

BMC Nephrology 1/2015 Go to the issue